Diopsys Inc. introduced a tabletop version of its electroretinography (ERG) and visual evoked potential (VEP) testing technology (ARGOS).
Las Vegas-Diopsys Inc. introduced a tabletop version of its electroretinography (ERG) and visual evoked potential (VEP) testing technology (ARGOS).
The device provides eye-care professionals (ECPs) with the same visual electrophysiology suite available in the company’s NOVA cart system, but in a tabletop version.
The company also announced a national rollout of its full-field electroretinography (ffERG) testing protocols, which will be available on both the ARGOS and NOVA systems. Previously only available in beta test sites, the ffERG tests use a handheld, mini-Ganzfeld dome to stimulate retinal cells.
The ffERG results may be used to indicate the level of functional loss on patients with maculopathies, and give ECPs the ability to measure the affect of maculopathies on vision through the presence of cataracts. The goal is to help ECPs better manage the patient and potential for IOL procedures.
“The launch of the [ARGOS] and the wider availability of full-field electroretinography testing demonstrates our commitment to being the leader in offering sophisticated yet versatile visual electrophysiology testing for the eye care professional,” said Joe Fontanetta, president and chief executive officer of Diopsys.
“ERG and VEP were typically reserved for laboratory and academic settings," Fontanetta said. "With the Diopsys NOVA system, and now ARGOS, eye-care specialists have the tools they need to perform objective, functional testing, which provides important information to help in early detection and better patient management.”